Related Experiment Video
Updated: May 4, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Recent advances in the diagnosis and management of cardiac amyloidosis
1Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, USA. sher.taimur@mayo.edu.
Insights
Cardiac amyloidosis, a heart condition, is often diagnosed late. Early detection and tailored treatments, including chemotherapy and transplantation, improve outcomes for this serious disease.
Area of Science:
- Cardiology
- Cardiovascular Diseases
- Amyloidosis Research
Background:
- Cardiac amyloidosis significantly contributes to patient morbidity and mortality.
- Delayed diagnosis is common due to nonspecific symptoms and challenges in early cardiac imaging detection.
Purpose of the Study:
- To review the diagnosis, treatment, and prognosis of cardiac amyloidosis.
- To highlight the impact of amyloid protein type on patient outcomes.
Main Methods:
- Review of current diagnostic approaches, including cardiac imaging.
- Summary of established and emerging therapeutic strategies based on amyloid type.
- Discussion of prognostic factors and supportive care.
Main Results:
- Treatment strategies vary significantly depending on the specific amyloid protein involved.
- Immunoglobulin light-chain amyloidosis is associated with poorer prognoses compared to other types.
- Ongoing clinical trials are exploring novel treatments like siRNA and protein stabilizers.
Conclusions:
- Cardiac amyloidosis requires timely diagnosis and individualized treatment plans.
- Advancements in cardiac imaging and proteomics are crucial for improving patient care.
- Supportive care remains fundamental in managing cardiac amyloidosis.
Abstract:
The heart is commonly involved in various forms of amyloidosis and cardiomyopathy is a major cause of morbidity and mortality in these patients. Diagnosis of cardiac amyloidosis is often delayed due to nonspecific presenting symptoms and failure to recognize early signs of amyloid heart disease on routine cardiac imaging. Treatment of cardiac amyloidosis depends upon the type of amyloid protein. Systemic chemotherapy with or without stem cell transplantation is used to treat immunoglobulin-related amyloidosis and liver transplantation is used for familial transthyretin amyloidosis in select patients. Clinical trials with siRNA for the treatment of transthyretin amyloid cardiomyopathies and amyloid protein stabilizers are ongoing. Prognosis depends on the type of amyloid protein with poorer outcomes noted in immunoglobulin light-chain amyloidosis. Supportive care forms the cornerstone of management and advancements in cardiac imaging and proteomics are expected to positively impact our ability to diagnose, prognosticate and treat cardiac amyloidosis.
More Related Videos
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis III: Medical Management
Acute Coronary Syndrome III: Diagnostic Studies

